Esperion Therapeutics Inc. Shares Near 52-Week Low - Market Mover
The shares closed 0.5% above its 52-week low of $4.13, with trading volume lower than its 30 day average
Jan 08, 2022 by Kwhen Finance Editors
Esperion Therapeutics Inc. (ESPR) shares closed today at 0.5% above its 52 week low of $4.13, giving the company a market cap of $120M. The stock is currently down 17.0% year-to-date, down 86.6% over the past 12 months, and down 69.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%.
Trading Activity
- Trading volume this week was 29.5% higher than the 20-day average.
- Beta, a measure of the stock’s volatility relative to the overall market stands at 0.8.
Technical Indicators
- The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.
- MACD, a trend-following momentum indicator, indicates a downward trend.
- The stock closed above its Bollinger band, indicating it may be overbought.
- The stock closed at 11.5% lower than its 5-day moving average, 17.0% lower than its 20-day moving average, and 52.8% lower than its 90-day moving average.
Market Comparative Performance
- The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis
- The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis
- The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis
| Name | DoD %Δ | YTD %Δ | 1 Yr % | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|
| Esperion Therapeutics Inc. | -5.0 | -17.0 | -86.6 | -89.0 | 5.6 |
| Dow Jones Industrial Average | -0.0 | -0.3 | 18.7 | -2.0 | 23.2 |
| S&P 500 Index | -0.4 | -1.9 | 24.6 | -2.5 | 28.8 |
| Health Care | -0.7 | -5.2 | 13.5 | -5.5 | 21.4 |
Peer Group Comparative Performance
- The company's stock price performance year-to-date lags the peer average by 164.6%
- The company's stock price performance over the past 12 months lags the peer average by 1594.4%
| Name | MKT CAP (USD) | P/E | YTD %Δ | 1 Yr %Δ | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|---|
| Esperion Therapeutics Inc. | ESPR | 0 | -17.0 | -86.6 | -89.0 | 5.6 |
| Peer Avg | N/A | 160.3 | -6.4 | -5.1 | -32.6 | 31.3 |
| Pfizer Inc. | PFE | 16.3 | -5.6 | 56.2 | -10.3 | 70.6 |
| Regeneron Pharmaceuticals, Inc. | REGN | 9.1 | -4.4 | 25.5 | -12.8 | 35.7 |
| Biomarin Pharmaceutical Inc. - Registered Shares | BMRN | 971.8 | -4.6 | -7.1 | -5.9 | 21.2 |
| Ultragenyx Pharmaceutical Inc. | RARE | -14.1 | -12.2 | -49.3 | -54.4 | 9.5 |
| Amicus Therapeutics Inc | FOLD | -13.3 | -1.2 | -52.2 | -48.9 | 41.6 |
| Lexicon Pharmaceuticals Inc | LXRX | -7.8 | -10.4 | -3.8 | -63.1 | 9.2 |
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.
Was this content valuable for you?
Tags: